ImmunityBio
Open
$7.10
Prev. Close
$7.10
High
$7.11
Low
$7.10
Market Snapshot
$6.86B
-19.5
-0.59
$14.75M
691
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 691 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
ImmunityBio is facing a class action lawsuit after a misleading FDA warning led to a 21% drop in its shares between January and March 2026.
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 691 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Recently from Cashu
ImmunityBio Secures $75 Million Amid Class Action Lawsuits and FDA Warning on Anktiva Claims
ImmunityBio Strengthens Financial Foundation Amid Class Action Lawsuits ImmunityBio has successfully secured $75 million in non-dilutive financing through a strategic deal with Oberland Capital. This…
ImmunityBio’s Anktiva Approved for BCG-Unresponsive Bladder Cancer Treatment, Transforming Patient Care
ImmunityBio's Breakthrough in Bladder Cancer Treatment ImmunityBio recently celebrates a significant development in oncology with the approval of its immunotherapy drug, Anktiva, in combination with B…
ImmunityBio's Anktiva Approved for Treating BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
ImmunityBio's Anktiva Approval Enhances Bladder Cancer Treatment Options ImmunityBio announces a major advancement in oncology with the recent approval of Anktiva for use in combination with Bacillus…
ImmunityBio Enhances NK Cell Therapy Production to Advance Immunotherapy Solutions
ImmunityBio Advances NK Cell Therapy Production ImmunityBio Inc. makes significant strides with its natural killer (NK) cell therapy platform, highlighting a pivotal moment for the company within the…